clofibrate has been researched along with Alloxan Diabetes in 15 studies
angiokapsul: contains clofibrate & insoitolnicotinate
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study was designed to characterise the influence of a novel acyl-CoA:cholesterol acyltransferase inhibitor, VULM 1457, on the severity of myocardial ischaemia-reperfusion injury in a model of diabetes mellitus and hypercholesterolaemia induced by co-administration of streptozotocin and a high fat-cholesterol diet." | 7.74 | The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo. ( Adameová, A; Faberová, V; Kuzelová, M; Ravingerová, T; Svec, P, 2007) |
| " On day 21 of pregnancy, placentas from control and diabetic rats were cultured in the presence of PPARα agonists (clofibrate and leukotriene B(4) (LTB(4))) for further evaluation of levels, synthesis, and peroxidation of lipids as well as NO production." | 3.77 | PPARα agonists regulate lipid metabolism and nitric oxide production and prevent placental overgrowth in term placentas from diabetic rats. ( Capobianco, E; Higa, R; Jawerbaum, A; Kurtz, M; Martínez, N; White, V, 2011) |
| "The study was designed to characterise the influence of a novel acyl-CoA:cholesterol acyltransferase inhibitor, VULM 1457, on the severity of myocardial ischaemia-reperfusion injury in a model of diabetes mellitus and hypercholesterolaemia induced by co-administration of streptozotocin and a high fat-cholesterol diet." | 3.74 | The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo. ( Adameová, A; Faberová, V; Kuzelová, M; Ravingerová, T; Svec, P, 2007) |
| "This study examined the effects of simvastatin (10 mg/ kg) and VULM 1457 (50 mg/kg), an ACAT inhibitor, in the heart model of 6 min ischemia followed by 10 min reperfusion injury in the diabetic-hypercholesterolaemic (DM-HCH) rats." | 3.73 | Protective effect of simvastatin and VULM 1457 in ischaemic-reperfused myocardium of the diabetic-hypercholesterolemic rats. ( Adameová, A; Faberová, V; Kuzelová, M; Svec, P, 2006) |
| "Insulin resistance is a characteristic feature of type II diabetes as well as obesity." | 2.41 | [Discovery and development of a new insulin sensitizing agent, pioglitazone]. ( Fujita, T; Ikeda, H; Kawamatsu, Y; Meguro, K; Sohda, T, 2002) |
| "The early stage of diabetic nephropathy (DN) is linked to proteinuria." | 1.35 | Glomerular 20-HETE, EETs, and TGF-beta1 in diabetic nephropathy. ( Chang, HH; Inscho, EW; Luo, P; Seki, T; Wang, CY; Wang, MH; Zhang, J; Zhou, Y, 2009) |
| "VULM 1457 is an ACAT inhibitor, which has expressed potent hypolipidemic and antiatherosclerotic effects in previous studies." | 1.33 | The hypolipidemic effect of a new ACAT inhibitor, VULM 1457, in diabetic-hypercholesterolaemic rats. ( Adameová, A; Faberová, V; Kuzelová, M; Svec, P, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (33.33) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Henke, BR | 1 |
| Blanchard, SG | 1 |
| Brackeen, MF | 1 |
| Brown, KK | 1 |
| Cobb, JE | 1 |
| Collins, JL | 1 |
| Harrington, WW | 1 |
| Hashim, MA | 1 |
| Hull-Ryde, EA | 1 |
| Kaldor, I | 1 |
| Kliewer, SA | 1 |
| Lake, DH | 1 |
| Leesnitzer, LM | 1 |
| Lehmann, JM | 1 |
| Lenhard, JM | 1 |
| Orband-Miller, LA | 1 |
| Miller, JF | 1 |
| Mook, RA | 1 |
| Noble, SA | 1 |
| Oliver, W | 1 |
| Parks, DJ | 1 |
| Plunket, KD | 1 |
| Szewczyk, JR | 1 |
| Willson, TM | 1 |
| Navarrete-Vázquez, G | 1 |
| Alaniz-Palacios, A | 1 |
| Hidalgo-Figueroa, S | 1 |
| González-Acevedo, C | 1 |
| Ávila-Villarreal, G | 1 |
| Estrada-Soto, S | 1 |
| Webster, SP | 1 |
| Medina-Franco, JL | 1 |
| López-Vallejo, F | 1 |
| Guerrero-Álvarez, J | 1 |
| Tlahuext, H | 1 |
| Luo, P | 1 |
| Zhou, Y | 1 |
| Chang, HH | 1 |
| Zhang, J | 1 |
| Seki, T | 1 |
| Wang, CY | 1 |
| Inscho, EW | 1 |
| Wang, MH | 1 |
| Martínez, N | 1 |
| Kurtz, M | 1 |
| Capobianco, E | 1 |
| Higa, R | 1 |
| White, V | 1 |
| Jawerbaum, A | 1 |
| Sohda, T | 1 |
| Kawamatsu, Y | 1 |
| Fujita, T | 1 |
| Meguro, K | 1 |
| Ikeda, H | 1 |
| Adameová, A | 3 |
| Kuzelová, M | 3 |
| Faberová, V | 3 |
| Svec, P | 3 |
| Ravingerová, T | 1 |
| Kawashima, Y | 2 |
| Kozuka, H | 2 |
| Katoh, H | 1 |
| Paul, HS | 1 |
| Adibi, SA | 1 |
| Hüdepohl, JM | 1 |
| Zielke, R | 1 |
| Rodrigues, B | 1 |
| Grassby, PF | 1 |
| Battell, ML | 1 |
| Lee, SY | 1 |
| McNeill, JH | 1 |
| Horie, S | 2 |
| Utsumi, K | 1 |
| Suga, T | 2 |
| Isobe, M | 1 |
1 review available for clofibrate and Alloxan Diabetes
| Article | Year |
|---|---|
[Discovery and development of a new insulin sensitizing agent, pioglitazone].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Diabetes Mellitus; Diabetes Mellitus, Experimental; D | 2002 |
14 other studies available for clofibrate and Alloxan Diabetes
| Article | Year |
|---|---|
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experime | 1998 |
Discovery, synthesis and in combo studies of a tetrazole analogue of clofibric acid as a potent hypoglycemic agent.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Binding Sites; Blood Glucose; Catalytic Domain | 2013 |
Glomerular 20-HETE, EETs, and TGF-beta1 in diabetic nephropathy.
Topics: 8,11,14-Eicosatrienoic Acid; Amino Acids; Animals; Clofibrate; Cytochrome P-450 CYP4A; Diabetes Mell | 2009 |
PPARα agonists regulate lipid metabolism and nitric oxide production and prevent placental overgrowth in term placentas from diabetic rats.
Topics: Animals; Cholesterol; Clofibrate; Diabetes Mellitus, Experimental; Female; Fetus; In Vitro Technique | 2011 |
The hypolipidemic effect of a new ACAT inhibitor, VULM 1457, in diabetic-hypercholesterolaemic rats.
Topics: Animals; Blood Glucose; Cholesterol; Cholesterol, Dietary; Clofibrate; Diabetes Mellitus, Experiment | 2005 |
Protective effect of simvastatin and VULM 1457 in ischaemic-reperfused myocardium of the diabetic-hypercholesterolemic rats.
Topics: Animals; Arrhythmias, Cardiac; Blood Glucose; Cholesterol; Cholesterol, Dietary; Clofibrate; Diabete | 2006 |
The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo.
Topics: Animals; Anti-Arrhythmia Agents; Cholesterol, Dietary; Clofibrate; Diabetes Mellitus, Experimental; | 2007 |
Increased activity of stearoyl-CoA desaturation in liver from rat fed clofibric acid.
Topics: Acyl Coenzyme A; Animals; Clofibrate; Clofibric Acid; Diabetes Mellitus, Experimental; Fatty Acid De | 1982 |
Differential effects of altered hormonal state on the induction of acyl-CoA hydrolases and peroxisomal beta-oxidation by clofibric acid.
Topics: Adrenalectomy; Animals; Clofibrate; Clofibric Acid; Dexamethasone; Diabetes Mellitus, Experimental; | 1983 |
Mechanism of activation of hepatic branched-chain alpha-ketoacid dehydrogenase by a muscle factor.
Topics: 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); Animals; Calcium; Clofibrate; Diabetes Mellitus, | 1983 |
[Formation and modification of bile lipids].
Topics: Animals; Bile; Cholelithiasis; Cholesterol; Clofibrate; Contraceptives, Oral, Hormonal; Diabetes Mel | 1983 |
Hypertriglyceridemia in experimental diabetes: relationship to cardiac dysfunction.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Cholesterol; Clofibrate; Diabetes Mellitus, Experim | 1994 |
Changes in the activities of dihydroxyacetone phosphate and glycerol-3-phosphate acyltransferases in rat liver under various conditions.
Topics: Acyltransferases; Animals; Clofibrate; Diabetes Mellitus, Experimental; Fasting; Glycerol-3-Phosphat | 1990 |
Changes in CoA pools in hepatic peroxisomes of the rat under various conditions.
Topics: Acetyl Coenzyme A; Acyl Coenzyme A; Animals; Centrifugation, Density Gradient; Clofibrate; Coenzyme | 1986 |